Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;36(3):101601.
doi: 10.1016/j.beem.2021.101601. Epub 2021 Nov 25.

Paraneoplastic autoimmune hypophysitis: An emerging concept

Affiliations
Review

Paraneoplastic autoimmune hypophysitis: An emerging concept

Hironori Bando et al. Best Pract Res Clin Endocrinol Metab. 2022 May.

Abstract

Pituitary autoimmunity is one of the principal causes of hypopituitarism. Additionally, hypophysitis is one of the immune-related adverse events associated with immunotherapy. Recent case-oriented research has revealed a novel type of autoimmune hypophysitis, anti-PIT-1 hypophysitis, related to isolated adrenocorticotropic hormone (ACTH) deficiency and immune checkpoint inhibitor-related hypophysitis, as a form of paraneoplastic syndrome. Under these conditions, the ectopic expression of pituitary antigens present in tumors evokes a breakdown of immune tolerance, resulting in the production of autoantibodies and autoreactive cytotoxic T cells that specifically harm pituitary cells. Consequently, an innovative clinical entity of paraneoplastic autoimmune hypophysitis has been purported. This novel concept and its underlying mechanisms provide clues for understanding the pathogenesis of autoimmune pituitary diseases and can be applied to other autoimmune diseases. This review discusses the etiology of paraneoplastic autoimmune hypophysitis and its future.

Keywords: anti-PIT-1 hypophysitis; immune-checkpoint inhibitor-related hypophysitis; isolated ACTH deficiency; paraneoplastic syndrome.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Y.T. has been an advisory board member and consultant for Novo Nordisk, Versartis, and Ascendis Pharma and accepted a research grant from Novo Nordisk and Ono Pharmaceutical.

Publication types

Supplementary concepts

LinkOut - more resources